New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2012
12:08 EDTDRI, MSPD, GERN, UEPS, BIDU, YOKU, SINA, PBY, BIG, GALEOn The Fly: Midday Wrap
Stocks on Wall Street were mixed at midday in a lackluster trading session, with the Dow the leader and the Nasdaq the laggard. In the latest chapter of the unfolding fiscal cliff drama, President Obama’s administration rejected a Republican plan that did not include higher tax rates for wealthy Americans. The next batch of cliff headlines may come from an interview that President Obama has scheduled for this afternoon on Bloomberg Television... ECONOMIC EVENTS: No major economic data was released in the U.S. Internationally, the Reserve Bank of Australia cut its key benchmark interest rate to 3.00% from 3.25%, as expected, and the Bank of Canada maintained its target for its overnight rate at 1%... COMPANY NEWS: Darden Restaurants (DRI), the parent company of Olive Garden, Red Lobster and LongHorn Steakhouse, warned its profit for the current quarter and the year may fall well short of analyst expectations. The company, whose shares tumbled nearly 10% after the outlook announcement, blamed failed promotions and negative press on its tests to limit rising health care costs for its under performance... Among companies reporting quarterly results, Big Lots (BIG) advanced 9.7% while Pep Boys (PBY) declined 13.7%... A number of U.S.-listed Chinese companies traded lower after the SEC charged the Chinese subsidiaries of the four major U.S. accounting firms with refusing to cooperate in investigations of alleged accounting fraud at Chinese companies. Shares of Sina (SINA), Youku Tudou (YOKU) and Baidu (BIDU) were among those declining following the news... MAJOR MOVERS: Among the notable gainers were Galena Biopharma (GALE), up almost 10% after signing a commercialization partnership for its NeuVax drug with Teva (TEVA), and Mindspeed Technologies (MSPD), up 7% after raising its Q1 revenue view. Among the noteworthy losers was Net 1 UEPS (UEPS), which plunged 56% after disclosing the DOJ and FBI are investigating the company for potential violations of the Foreign Corrupt Practices Act. Also lower were shares of Geron (GERN), down 25% after it discontinued development of a treatment for brain cancer, announced job cuts and said its CFO is leaving the company to pursue other opportunities... INDICES: Near noon, the Dow was up 15.36, or 0.12%, to 12,980.96; the Nasdaq was down 11.77, or 0.39%, to 2,990.43; and the S&P 500 was down 1.88, or 0.13%, to 1,407.58.
News For DRI;BIG;PBY;SINA;YOKU;BIDU;UEPS;GERN;MSPD;GALE From The Last 14 Days
Check below for free stories on DRI;BIG;PBY;SINA;YOKU;BIDU;UEPS;GERN;MSPD;GALE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 25, 2014
09:09 EDTBIDUBaidu price target raised to $260 from $220 at Pacific Crest
Subscribe for More Information
08:06 EDTBIDUBaidu price target raised to $275 from $220 at Brean Capital
Subscribe for More Information
07:46 EDTBIDUBaidu price target raised to $250 from $215 at Stifel
Subscribe for More Information
July 24, 2014
18:45 EDTBIDUOn The Fly: After Hours Movers
Subscribe for More Information
16:51 EDTBIDUBaidu up 7% to $218.34 after Q2 report
Subscribe for More Information
16:37 EDTBIDUBaidu sees Q3 revenue $2.163B-$2.221B
Subscribe for More Information
16:35 EDTBIDUBaidu reports Q2 EPS ex-items $1.73, consensus $1.40
Subscribe for More Information
15:29 EDTBIDUNotable companies reporting after market close
Subscribe for More Information
13:45 EDTDRIStarboard files complaint to inspect Darden books
Subscribe for More Information
13:33 EDTBIDUBaidu July weekly 202 straddle priced for 6.7% move into Q2
Subscribe for More Information
11:57 EDTBIDUBaidu technical commentary ahead of results
Subscribe for More Information
July 23, 2014
11:38 EDTDRIBrinker retreats after analyst downgrades on industry concerns
Subscribe for More Information
09:23 EDTBIDUBaidu volatility elevated into Q2 and outlook
Baidu July weekly call option implied volatility is at 107, August is at 45, September is at 39, December is at 37; compared to its 26-week average of 42 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on July 24.
July 22, 2014
15:46 EDTGALEGalena in-license of Zuplenz makes sense, says Piper Jaffray
Subscribe for More Information
09:55 EDTGALEGalena 'stands little chance' of improving Zuplenz sales, TheStreet says
After Galena BioPharma entered into a license agreement with MonoSol Rx for Zuplenz, TheStreet's Adam Feuerstein predicted that the company "stands little chance of delivering higher sales of Zuplenz than its previous marketer," calling the drug one that "no one wants" and "something to promote while waiting for the phase III study of NeuVax in breast cancer to inevitably fail." Reference Link
07:21 EDTGALEGalena enters into licensing agreement with MonoSol Rx
MonoSol Rx announced that it has licensed Zuplenz to Galena Biopharma. Zuplenz is an oral soluble film, or OSF, for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting. The licensing agreement includes an undisclosed upfront payment from Galena, as well as double digit royalty payments from sales of Zuplenz. Zuplenz is the first oral soluble lingual film product approved by the FDA as a prescription medication, based on MonoSol Rx's proprietary PharmFilm technology.
July 21, 2014
10:49 EDTSINA, BIDUBaidu advances following Morgan Stanley upgrade
Subscribe for More Information
07:26 EDTBIDUBaidu upgraded to Overweight from Equal Weight at Morgan Stanley
Subscribe for More Information
July 18, 2014
10:38 EDTPBYAutoZone, O'Reilly drop following Stifel downgrades
Subscribe for More Information
05:21 EDTBIDUChangyou.com appoints Rucia Ren as acting CFO
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use